ScreenPro FH – projekt v oblasti screeningu zaměřený na familiární hypercholesterolemii ve střední, jižní a východní Evropě: odůvodnění a záměr

English version České info

Familiární hypercholesterolemie (FH) je geneticky podmíněné onemocnění s velmi dobře popsaným genetickým přenosem a klinickým průběhem. I přes významný pokrok v nedávné době je familiární hypercholesterolemie dosud podceňovaná, nedostatečně diagnostikovaná a tedy i nedostatečně léčená. Jako společný rizikový faktor předčasného vzniku kardiovaskulárního onemocnění navíc představuje důležitou výzvu v oblasti zdravotní péče. Projekt ScreenPro FH je zaměřen na rozvoj mezinárodní sítě, která podpoří zkvalitňování komplexní péče – od včasného screeningu přes stanovení diagnózy až k nejmodernější léčbě familiární hypercholesterolemie ve střední, východní a jižní Evropě. Důležitým úkolem projektu je harmonizovat a sjednotit diagnostické a terapeutické přístupy v jednotlivých zúčastněných zemích, v nichž je situace v každé z nich odlišná. Země s většími zkušenostmi by měly sloužit jako vzor pro ty, které svou síť FH nyní budují.

Klíčová slova:
familiární hypercholesterolemie – screening – diagnóza – optimalizace léčby

Autoři: Richard Češka ¹; György Paragh ²; Željko Reiner ³; Maciej Banach ⁴; Lale Tokgözoğlu ⁵; Andrey; V. Susekov ⁶; Katarína Rašlová ⁷; Tomáš Freiberger ^8,9; Branislav Vohnout ^7,10; Andrzej Rynkiewicz ¹¹; Assen Goudev ¹²; Gheorghe-Andrei Dan ¹³; Dan Gaiţă ¹⁴; Belma Pojskić ¹⁵; Ivan Pećin ³; Meral Kayıkçıoğlu ¹⁶; Olena Mitchenko ¹⁷; Marat V. Ezhov ¹⁸; Gustavs Latkovskis ¹⁹; Žaneta Petrulionienė ²⁰; Zlatko Fras ²¹; Nebojsa Tasić ²²; Erkin M. Mirrakhimov ²³; Tolkun Murataliev ²³; Alexander B. Shek ²⁴; Vladimír Tuka ¹; Alexandros D. Tselepis ²⁵; Elie M. Moubarak ²⁶; Khalid Al Rasadi ²⁷
Působiště autorů: Paul Stradins Clinical University Hospital, Riga, Latvia ; Third Department of Medicine – Department of Endocrinology and Metabolism of the First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic ¹; Institute of Internal Medicine, University of Debrecen Faculty of Medicine, Debrecen, Hungary ²; Department of Internal Medicine, Division of Metabolic Diseases, School of Medicine University of Zagreb, University Hospital Centre Zagreb, Zagreb, Croatia ³; Department of Hypertension, Medical University of Lodz, Lodz, Poland ⁴; Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey ⁵; Department of clinical Pharmacology and therapeutics, Academy for Postgraduate Education, Ministry of Health, Russian Federation ⁶; Coordination Centre for Familial Hyperlipidemias, Slovak Medical University, Bratislava, Slovakia ⁷; Molecular Genetics Lab, Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic ⁸; Medical Faculty, Masaryk University, Brno, Czech Republic ⁹; Institute of Nutrition, FOaZOS, Slovak Medical University, Bratislava, Slovakia ¹⁰; Department of Cardiology and Cardiosurgery, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland ¹¹; Queen Giovanna University Hospital, Sofia, Bulgaria ¹²; University of Medicine Carol Davila, Colentina University Hospital, Bucharest, Romania ¹³; University of Medicine & Pharmacy Victor Babes, Institute of Cardiovascular Diseases, CardioPrevent Foundation Timisoara, Romania ¹⁴; Cantonal hospital, Zenica, Bosnia and Herzegovina ¹⁵; Cardiology Department, Ege University Medical School, Lipid Clinic, Izmir, Turkey ¹⁶; Institute of Cardiology, AMS Ukraine Dyslipidemia Department, Kiev, Ukraine ¹⁷; Russian Cardiology Research and Production Centre, Moscow, Russian Federation ¹⁸; Latvian Institute of Cardiology and Regenerative Medicine, Faculty of Medicine, University of Latvia ¹⁹; Centre of Cardiology and Angiology, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania ²⁰; Division of Internal Medicine, Preventive Cardiology Unit and Medical Faculty, University of Ljubljana, University Medical Centre, Ljubljana, Slovenia ²¹; Cardiovascular Research Centre, Cardiovascular Institute “Dedinje”, Belgrade, Serbia ²²; National Centre of Cardiology and Therapy named after academician Mirsaid Mirrakhimov, Kyrgyz State Medical Academy naved after I. K. Akhunbaev, Bishkek, Kyrgyzstan ²³; Republican Specialized Centre of Cardiology, Tashkent, Uzbekistan ²⁴; Department of Chemistry, University of Ioannina, Atherothrombosis Research Centre, Ioannina, Greece ²⁵; LDL apheresis Centre, Dahr El Bachek Government University Hospital – DGUH, Roumieh – Lebanon ²⁶; College of Medicine and Health Science at Sultan Qaboos University, Sultan Qaboos University Hospital, Muscat, Oman ²⁷
Vyšlo v časopise: Vnitř Lék 2017; 63(1): 43-48
Kategorie: Přehledné referáty

Souhrn

Klíčová slova:
familiární hypercholesterolemie – screening – diagnóza – optimalizace léčby

Zdroje

1. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D et al. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis 2015; 243(1): 257–259. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.021>.

2. Benn M, Watts GF, Tybjaerg-Hansen A et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97(11): 3956–3964. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012–1563>.

3. Neil HA, Hammond T, Huxley R et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000; 321(7254): 148.

4. Marks D, Thorogood M, Neil HA et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168(1):1–14.

5. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 2(7635): 1380–1382.

6. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303(6807): 893–896.

7. Cuchel M, Bruckert E, Ginsberg HN et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35(32): 2146–2157. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu274>.

8. Catapano AL, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(39):2999–3058. Dostupné z DOI: <http://doi.10.1093/eurheartj/ehw272>.

9. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.a2423>.

10. Neil A, Cooper J, Betteridge J et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29(21): 2625–2633. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn422>.

11. Umans-Eckenhausen MA, Defesche JC, van Dam MJ et al. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003; 163(1): 65–68.

12. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357(9251): 165–168.

13. Watts GF, Juniper A, van Bockxmeer F et al. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. Int J Evid Based Healthc 2012; 10(3): 211–221. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1744–1609.2012.00272.x>.

14. Ceska R, Freiberger T, Vaclova M et al. Familial Hypercholesterolemia. Triton: Praha 2015. ISBN 978–80–7387–953–2.

15. Al-Rasadi K, Al-Waili K, Al-Sabti HA et al. Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J 2014; 29(2): 85–91. Dostupné z DOI: <http://dx.doi.org/10.5001/omj.2014.22>.

16. Green P, Neely D, Humphries SE. [Medway FH Audit Steering Committee]. Improving detection of familial hypercholesterolaemia in primary care using electronic audit and nurse-led clinics. J Eval Clin Pract 2016; 22(3): 341–348. Dostupné z DOI: <http://dx.doi.org/10.1111/jep.12481>.

17. Watts GF, Ding PY, George P et al. Translational Research for Improving the Care of Familial Hypercholesterolemia: The „Ten Countries Study“ and Beyond. J Atheroscler Thromb 2016; 23(8): 891–900. Dostupné z DOI: <http://dx.doi.org/10.5551/jat.35949>.

18. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36(36): 2425–2437. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv157>.

19. Goldberg AC, Hopkins PN, Toth PP et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S1-S8. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2011.04.003>.

20. Pang J, Poulter EB, Bell DA et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. J Clin Lipidol 2015; 9(5): 703–708. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacl.2015.07.005>.

21. Pang J, Lansberg PJ, Watts GF. International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next? J Atheroscler Thromb 2016; 23(5): 505–519. Dostupné z DOI: <http://dx.doi.org/10.5551/jat.34108>.

22. Santos RD, Gidding SS, Hegele RA et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016; 4(10): 850–861. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(16)30041–9>.

23. Richter WO, Donner MG, Hofling B et al. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998; 47(7): 863–868.